Half-year report · Q2
2590.TEDINET S100WMQW
Period2025-01-21 → 2025-07-20
Filed2025-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥117.7bn | 2025-01-21 → 2025-07-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.6bn | 2024-01-21 → 2024-07-20 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-21 → 2024-07-20 | Cons. | Operating income |
| Ordinary income | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2024-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥6.5bn | 2024-01-21 → 2024-07-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.9bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss |
| Net income | ¥4.7bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss |
| Total assets | ¥196.2bn | at 2025-07-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥200.3bn | at 2024-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.5bn | at 2025-07-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥90.7bn | at 2025-07-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥94.2bn | at 2024-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2025-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.9bn | at 2025-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥36.3bn | at 2024-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.1bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.5bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.2bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.1bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-43.05 | 2025-01-21 → 2025-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥155.36 | 2024-01-21 → 2024-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.1% | at 2024-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2025-07-20 | −¥506m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥65m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥2.0bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥184m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥530m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥3.1bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥7.0bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥6.8bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥158m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥463m |
| —segment total | revenue | 2025-01-21 → 2025-07-20 | ¥117.9bn |
| —segment total | revenue external | 2025-01-21 → 2025-07-20 | ¥117.7bn |
| —segment total | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥228m |
| —segment total | segment profit | 2025-01-21 → 2025-07-20 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2024-07-20 | −¥674m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥17m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥238m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥295m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥899m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥2.3bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥6.9bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥6.7bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥146m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥324m |
| —segment total | revenue | 2024-01-21 → 2024-07-20 | ¥117.7bn |
| —segment total | revenue external | 2024-01-21 → 2024-07-20 | ¥117.6bn |
| —segment total | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥167m |
| —segment total | segment profit | 2024-01-21 → 2024-07-20 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 2957000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -674000000 | JPY |
| Operating income | Prior1YTDDuration | 2282000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 71457000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 28756000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6831000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 10391000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | 263000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 117701000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 117701000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 65000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 158000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 228000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -228000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 71523000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 28756000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6990000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 10395000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | 263000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 117929000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -228000000 | JPY |
| Net sales | CurrentYTDDuration | 117701000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | -2031000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 3111000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 463000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 530000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -184000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1888000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -506000000 | JPY |
| Operating income | CurrentYTDDuration | 1381000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-09-03 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第51期中（自 2025年1月21日 至 2025年7月20日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ダイドーグループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | DyDo GROUP HOLDINGS,INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 髙松 富也 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪市北区中之島二丁目2番7号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06（7166）0011 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役執行役員財務部長 殿勝 直樹 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪市北区中之島二丁目2番7号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06（6222）2641 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役執行役員財務部長 殿勝 直樹 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |